Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Burkitt Lymphoma 5Recurrence 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Leukemia 2Neoplasms 1Lymphoproliferative Disorders 1Immunoproliferative Disorders 1Down Syndrome 1

Interventions

Dexamethasone 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Vorinostat 1Rituximab 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Daunorubicin 1Cytarabine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Immunoproliferative Disorders × blinatumomab × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡